ストックスクリーナーアプリを入手
2.74
34.61%
-1.45
プレマーケット:
2.71
-0.03
-1.09%
前日終値:
$4.19
開ける：
$3.01
24時間の取引高:
14.03M
Relative Volume:
8.40
時価総額：
$253.92M
収益：
-
当期純損益:
$-39.95M
株価収益率:
-5.8937
EPS:
-0.4649
ネットキャッシュフロー:
$-34.08M
1週間 パフォーマンス:
-35.68%
1か月 パフォーマンス:
-37.73%
6か月 パフォーマンス:
-67.76%
1年 パフォーマンス:
-71.34%
1日の値動き範囲:
$2.61
$3.115
1週間の範囲:
$2.61
$4.605
52週間の値動き範囲:
$2.61
$13.99
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
名前
Anavex Life Sciences Corporation
セクター
電話
844-689-3939
住所
630 5TH AVENUE, NEW YORK
Compare AVXL vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
2.74 | 253.92M | 0 | -39.95M | -34.08M | -0.4649 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-12-06 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-23 | 開始されました | Berenberg | Buy |
| 2021-09-23 | 開始されました | BTIG Research | Buy |
| 2020-12-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-09-28 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-02-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-06-18 | 開始されました | Janney | Buy |
| 2018-05-16 | 再開されました | Maxim Group | Buy |
| 2018-03-08 | 開始されました | ROTH Capital | Buy |
| 2018-02-13 | 繰り返されました | Maxim Group | Buy |
| 2017-09-29 | 再開されました | Noble Financial | Buy |
| 2017-02-07 | 開始されました | Noble Financial | Buy |
| 2016-03-29 | 開始されました | FBR Capital | Outperform |
すべてを表示
Anavex Life Sciences Corporation (AVXL) 最新ニュース
AVXL Plummets 31% to 52-Week Lows: A Technical Meltdown Ignites the Biotech Watchlist - Bitget
Anavex Life Sciences withdraws EU marketing application for blarcamesine after CHMP feedback - TradingView
Anavex (NASDAQ: AVXL) withdraws EU Alzheimer’s drug application for blarcamesine - Stock Titan
Crude Oil Moves Lower; Cintas Raises FY2026 Forecast - Benzinga
Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings - Benzinga
Anavex Life Sciences Corp Faces Competitive Pressure Amid Financial Year Results - StocksToTrade
Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback - Benzinga
Anavex Life Sciences Corp. (AVXL) recently disclosed the latest updates on the regulatory review of its investigational drug Blarcamesine for early Alzheimer’s disease in the European Union. - Bitget
Anavex Life Sciences stock tumbles after EU filing withdrawal By Investing.com - Investing.com UK
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease - marketscreener.com
EU review halts Anavex’s Alzheimer’s drug bid, more data next - Stock Titan
Anavex Life lead drug targets early Alzheimer's causenew study highlights - MSN
AVXL Stock Soars After Anavex’s New Data Suggests Its Alzheimer’s Drug May Slow Brain Shrinkage - Stocktwits
D. Boral Capital Reiterates Buy Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease - The Manila Times
Study ties oral Alzheimer’s drug to slower brain shrinkage - Stock Titan
AVXL Technical Analysis | Trend, Signals & Chart Patterns | ANAVEX LIFE SCIENCES CORP (NASDAQ:AVXL) - ChartMill
Anavex Life Lead Drug Targets Early Alzheimer's CauseNew Study Highlights - Sahm
Form 8K Anavex Life Sciences Corp For: 9 February - Investing.com
Anavex Life Sciences Announces New Study Linking Autophagy Dysfunction to Alzheimer’s Disease Pathology - Quiver Quantitative
New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease - The Manila Times
Alzheimer’s study points to cell-cleanup failure before plaques form - Stock Titan
AVXL Stock Price, Quote & Chart | ANAVEX LIFE SCIENCES CORP (NASDAQ:AVXL) - ChartMill
Anavex Life Sciences Reports Positive Data for Blarcamesine in New Parkinson’s Disease Model at AD/PD™ 2026 Conference - Quiver Quantitative
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference - The Manila Times
Parkinson’s therapy hope: blarcamesine regrows nerve fibers in lab model - Stock Titan
Anavex Life Sciences (NASDAQ:AVXL) Stock Price Crosses Above 50 Day Moving AverageTime to Sell? - MarketBeat
Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's - MSN
Anavex Life Sciences Stock Rises After Experimental Alzheimer’s Drug Slows Cognitive Decline In Study - MSN
AVXL SEC FilingsAnavex Life Scie 10-K, 10-Q, 8-K Forms - Stock Titan
Earnings Update: Is Anavex Life Sciences Corp a top pick in the sectorM&A Rumor & Fast Gaining Stock Reports - baoquankhu1.vn
Anavex Life Sciences Touts Oral Alzheimer’s Drug Blarcamesine Data, Cash Runway at Healthcare Conference - Yahoo Finance
Anavex Life Sciences (NASDAQ:AVXL) Stock Price Passes Above Fifty Day Moving AverageWhat's Next? - MarketBeat
What's Going On With Anavex Life Sciences Stock On Wednesday? - Benzinga
Anavex Life Sciences to Present at the Citizens Life Sciences Conference - Anavex Life Sciences
Alzheimer's-focused Anavex CEO to speak at Citizens Life Sciences Conference - Stock Titan
Anavex Life Sciences Corp. (AVXL): Investor Outlook on a Biotechnology Stock with a Potential 393% Upside - DirectorsTalk Interviews
Anavex Adds Veteran Healthcare Leader to Board of Directors - The Globe and Mail
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference - Bitget
Anavex Life Sciences Corp. CEO to Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026 - Quiver Quantitative
Alzheimer’s treatment developer Anavex to speak at TD Cowen health conference - Stock Titan
Anavex Life Sciences (NASDAQ:AVXL) Shares Cross Below 50-Day Moving AverageHere's What Happened - MarketBeat
EBITDA per share of Anavex Life Sciences Corp. – LSE:0HFR - TradingView
Anavex Life Sciences appoints Dr. Axel Paeger to board By Investing.com - Investing.com India
Anavex Life Sciences appoints Dr. Axel Paeger to board - Investing.com
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors - marketscreener.com
Anavex Life Sciences Corp. (AVXL) Stock Analysis: Unveiling a Remarkable 433.98% Potential Upside - DirectorsTalk Interviews
Why analysts upgrade Anavex Life Sciences Corp. stockAnalyst Upgrade & AI Powered Buy/Sell Recommendations - mfd.ru
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update - Anavex Life Sciences
Anavex Life Sciences (NASDAQ:AVXL) Upgraded at Wall Street Zen - MarketBeat
Anavex Life Sciences Corporation (AVXL) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):